

## **Timolol Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.17	28.09.2024	1609200-00019	Date of first issue: 01.05.2017

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier						
	Trade name	:	Timolol Formulation				
1.2	1.2 Relevant identified uses of the substance or mixture and uses advised against						
	Use of the Sub- stance/Mixture	:	Pharmaceutical				
	Recommended restrictions on use	:	Not applicable				
1.3	Details of the supplier of the	saf	ety data sheet				
	Company	:	MSD Kilsheelan Clonmel Tipperary, IE				
	Telephone	:	353-51-601000				
	E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com				

### 1.4 Emergency telephone number

+1-908-423-6000

### **SECTION 2: Hazards identification**

#### 2.1 Classification of the substance or mixture

#### Classification (REGULATION (EC) No 1272/2008)

Specific target organ toxicity - repeated	H372: Causes da
exposure, Category 1, Cardio-vascular	longed or repeat
system, Lungs	

damage to organs through proated exposure.

#### 2.2 Label elements

### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms	:	
Signal word	:	Danger
Hazard statements	:	H372 Causes damage to organs (Cardio-vascular system, Lungs) through prolonged or repeated exposure.



## **Timolol Formulation**

Version 2.17	Revision Date: 28.09.2024	SDS Number: 1609200-00019		Date of last issue: 06.04.2024 Date of first issue: 01.05.2017
Preca	utionary statements	: Preve		
		P264 P270		n thoroughly after handling. t, drink or smoke when using this product.
		Respo	onse:	
		P314	Get medic	al advice/ attention if you feel unwell.

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### **SECTION 3: Composition/information on ingredients**

### 3.2 Mixtures

### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
(S)-3-[3-(tert-butylamino)-2- hydroxypropoxy]-4-morpholino-1,2,5- thiadiazole monomaleate	26921-17-5 248-111-5	Acute Tox. 4; H302 Repr. 2; H361d STOT RE 1; H372 (Lungs, Cardio- vascular system)	>= 0,1 - < 1

For explanation of abbreviations see section 16.

### **SECTION 4: First aid measures**

### 4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).



## **Timolol Formulation**

ersion .17	Revision Date: 28.09.2024		0S Number: 09200-00019	Date of last issue: 06.04.2024 Date of first issue: 01.05.2017
lf inha	aled	:	If inhaled, remov Get medical atte	
In case of skin contact		:	of water. Remove contam Get medical atte Wash clothing b	
In cas	se of eye contact	:		water as a precaution. Intion if irritation develops and persists.
lf swa	allowed	:	Get medical atte	D NOT induce vomiting. ention. proughly with water.
<b>.2 Most</b> i Risks	important symptoms a	nd e :		te and delayed to organs through prolonged or repeated
<b>.3 Indica</b> Treat	-	meo :		nd special treatment needed tically and supportively.
ECTION	N 5: Firefighting meas	sur	es	
.1 Extinc	guishing media			
-	ble extinguishing media	:	Water spray Alcohol-resistan Carbon dioxide Dry chemical	
Unsu media	itable extinguishing a	:	None known.	
.2 Sneci	al hazards arising from	the	substance or m	ixture
•	ific hazards during fire-			nbustion products may be a hazard to health.
	rdous combustion prod-		Carbon oxides	

### 5.3 Advice for firefighters

ucts

Special protective equipment	:	In the event of fire, wear self-contained breathing apparatus.
for firefighters		Use personal protective equipment.

Phosphorus compounds

Metal oxides



## **Timolol Formulation**

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 06.04.2024
2.17		1609200-00019	Date of first issue: 01.05.2017
Specif ods	ic extinguishing meth-	cumstances and Use water spray	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. aged containers from fire area if it is safe to do

### **SECTION 6:** Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
6.2 Environmental precautions		
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up	<ul> <li>Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.</li> <li>Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.</li> </ul>

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

### **SECTION 7: Handling and storage**

### 7.1 Precautions for safe handling

Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation Advice on safe handling	<ul> <li>Use only with adequate ventilation.</li> <li>Do not breathe mist or vapours. Do not swallow. Avoid contact with eyes.</li> </ul>

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Timolol Formulation**

Version 2.17	Revision Date: 28.09.2024		Number: 0200-00019	Date of last issue: 06.04.2024 Date of first issue: 01.05.2017
Hygie	ne measures	V F S C T E II ff T F R F I I I I I I I I I I I I I I I I I	<ul> <li>Avoid prolonged or repeated contact with skin.</li> <li>Wash skin thoroughly after handling.</li> <li>Handle in accordance with good industrial hygiene and practice, based on the results of the workplace exposu sessment</li> <li>Do not eat, drink or smoke when using this product.</li> <li>Take care to prevent spills, waste and minimize release environment.</li> <li>If exposure to chemical is likely during typical use, prov flushing systems and safety showers close to the worki place. When using do not eat, drink or smoke. Wash conated clothing before re-use.</li> <li>The effective operation of a facility should include revie engineering controls, proper personal protective equipr appropriate degowning and decontamination procedure industrial hygiene monitoring, medical surveillance and use of administrative controls.</li> </ul>	
7.2 Condit	ions for safe storage,	inclue	ding any incom	patibilities
	rements for storage and containers			abelled containers. Store in accordance with onal regulations.
Advic	e on common storage	S S C E	<ul> <li>Do not store with the following product types: Strong oxidizing agents Self-reactive substances and mixtures Organic peroxides Explosives Gases</li> </ul>	
•	<b>ic end use(s)</b> fic use(s)	: N	Vo data available	


### **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters

### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
(S)-3-[3-(tert- butylamino)-2- hydroxypropoxy]-4- morpholino-1,2,5- thiadiazole monomaleate	26921-17-5	TWA	10 μg/m3 (OEB 3)	Internal
	Further information: Eye, Skin			
		Wipe limit	100 μg/100 cm²	Internal

### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006





## **Timolol Formulation**

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 06.04.2024
2.17		1609200-00019	Date of first issue: 01.05.2017

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
Disodium hy- drogenorthophos- phate	Workers	Inhalation	Long-term systemic effects	4,07 mg/m3
	Consumers	Inhalation	Long-term systemic effects	3,04 mg/m3

### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Disodium hydrogenorthophos-	Fresh water	0,05 mg/l
phate		
	Marine water	0,005 mg/l
	Intermittent use/release	0,5 mg/l
	Sewage treatment plant	50 mg/l

#### 8.2 Exposure controls

### Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

#### Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially
		contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to NS EN 143
Filter type	:	Particulates type (P)



## **Timolol Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.17	28.09.2024	1609200-00019	Date of first issue: 01.05.2017

### **SECTION 9: Physical and chemical properties**

#### 9.1 Information on basic physical and chemical properties

Physical state	:	Aqueous solution
Colour	:	Colorless to pale yellow
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	No data available
Flash point Auto-ignition temperature	:	
Auto-ignition temperature	:	No data available
Auto-ignition temperature Decomposition temperature	:	No data available No data available No data available
Auto-ignition temperature Decomposition temperature pH Viscosity	: :	No data available No data available No data available No data available
Auto-ignition temperature Decomposition temperature pH Viscosity Viscosity, kinematic Solubility(ies)	:	No data available No data available No data available No data available
Auto-ignition temperature Decomposition temperature pH Viscosity Viscosity, kinematic Solubility(ies) Water solubility Partition coefficient: n-	::	No data available No data available No data available No data available soluble
Auto-ignition temperature Decomposition temperature pH Viscosity Viscosity, kinematic Solubility(ies) Water solubility Partition coefficient: n- octanol/water	::	No data available No data available No data available No data available soluble No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Timolol Formulation**

Version 2.17	Revision Date: 28.09.2024	SDS Num 1609200-0		Date of last issue: 06.04.2024 Date of first issue: 01.05.2017
	cle characteristics article size	: Not a	pplicable	
9.2 Other	information			
Explo	osives	: Not ex	xplosive	
Oxid	zing properties	: The s	ubstance or	mixture is not classified as oxidizing.
Evap	oration rate	: No da	ita available	
Mole	cular weight	: Not a	pplicable	

### **SECTION 10: Stability and reactivity**

## 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : None known.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

### **SECTION 11: Toxicological information**

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation exposure Skin contact Ingestion Eye contact

### Acute toxicity

Not classified based on available information.

### **Components:**

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate: Acute oral toxicity : LD50 (Rat): 1.000 mg/kg

LD50 (Mouse): 1.140 mg/kg



## **Timolol Formulation**

Version 2.17	Revision Date: 28.09.2024		DS Number: 609200-00019	Date of last issue: 06.04.2024 Date of first issue: 01.05.2017
	e toxicity (other routes o nistration)	f :	LD50 (Mouse): 30 Application Route	
			LD50 (Mouse): 80 Application Route	
Skin	corrosion/irritation			

Not classified based on available information.

### Components:

### (S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Species	:	Rabbit
Method	:	Draize Test
Result	:	No skin irritation

### Serious eye damage/eye irritation

Not classified based on available information.

### Components:

### (S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Species Result	-	Rabbit Mild eye irritation
Species Result		Dog No eye irritation

### Respiratory or skin sensitisation

### Skin sensitisation

Not classified based on available information.

### Respiratory sensitisation

Not classified based on available information.

### Germ cell mutagenicity

Not classified based on available information.

### **Components:**

### (S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: negative
Genotoxicity in vivo	:	Test Type: In vivo micronucleus test Species: Mouse Method: OECD Test Guideline 474 Result: negative

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Timolol Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.17	28.09.2024	1609200-00019	Date of first issue: 01.05.2017

### Carcinogenicity

Not classified based on available information.

### **Components:**

### (S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Species Application Route Exposure time LOAEL Result Target Organs Remarks	:	Rat Oral 2 Years 300 mg/kg body weight negative Adrenal gland The significance of these findings for humans is not certain.
Species Application Route Exposure time LOAEL Result Target Organs Remarks	:	Mouse, female Oral 18 Months 500 mg/kg body weight negative Lungs, Mammary gland, Uterus (including cervix) The significance of these findings for humans is not certain.
Carcinogenicity - Assess- ment	:	Weight of evidence does not support classification as a car- cinogen

### Reproductive toxicity

Not classified based on available information.

### **Components:**

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:				
Effects on fertility :	Test Type: Fertility/early embryonic development Species: Rat Application Route: Oral Fertility: NOAEL Mating/Fertility: 150 mg/kg body weight Early Embryonic Development: NOAEL F1: 150 mg/kg body weight			
Effects on foetal develop- : ment	Test Type: Embryo-foetal development Species: Rabbit Developmental Toxicity: LOAEL F1: 50 mg/kg body weight Result: Some evidence of adverse effects on development, based on animal experiments.			
Reproductive toxicity - As- : sessment	Some evidence of adverse effects on development, based on animal experiments.			

### STOT - single exposure

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Timolol Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.17	28.09.2024	1609200-00019	Date of first issue: 01.05.2017

### STOT - repeated exposure

Causes damage to organs (Cardio-vascular system, Lungs) through prolonged or repeated exposure.

### Product:

Target Organs	:	Cardio-vascular system, Lungs
Assessment		Causes damage to organs through prolonged or repeated
		exposure.

### **Components:**

### (S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Target Organs	:	Lungs, Cardio-vascular system
Assessment	:	Causes damage to organs through prolonged or repeated
		exposure.

### **Repeated dose toxicity**

### **Components:**

### (S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Species	:	Rat
NOAEL	:	25 mg/kg
Application Route	:	Oral
Exposure time	:	67 Weeks
-		
Species	:	Dog
Species NOAEL	:	Dog 10 mg/kg
•	:	0
NOAEL	:	10 mg/kg
NOAEL Application Route	:	10 mg/kg Oral

### Aspiration toxicity

Not classified based on available information.

### 11.2 Information on other hazards

### Endocrine disrupting properties

#### Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

#### Experience with human exposure

### Product:

General Information	:	May cause Stomach/intestinal disorders
		Respiratory disorders



## **Timolol Formulation**

Version 2.17	Revision Date: 28.09.2024	SDS Number: 1609200-00019	Date of last issue: 06.04.2024 Date of first issue: 01.05.2017
		effects	egular cardiac activity, central nervous system
Eye c	contact	: Symptoms: bu	rning or stinging of the eye
Com	ponents:		
(S)-3-	-[3-(tert-butylamino)-	2-hydroxypropoxy]-4	4-morpholino-1,2,5-thiadiazole monomaleate:
Eye c	contact	eyes, Headach	rning or stinging of the eye, dryness of the ne, Nausea, Dizziness, dry mouth, changes in s, Allergic reactions
Inges	tion	: Symptoms: He trointestinal dis	adache, Fatigue, Respiratory disorders, Gas- comfort, Allergic reactions, Rash, hair loss, status, Dizziness, changes in libido

### **SECTION 12: Ecological information**

### 12.1 Toxicity

### Components:

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:				
Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): 411 mg/l Exposure time: 96 h		
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 161 mg/l Exposure time: 48 h Method: OECD Test Guideline 202		
Toxicity to microorganisms	:	EC50 : > 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition		
		EC50 (Photobacterium phosphoreum): > 1.800 mg/l		

### 12.2 Persistence and degradability

### Components:

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:			
Biodegradability		Result: Not readily biodegradable. Biodegradation: 0 % Exposure time: 30 d	
Stability in water		Hydrolysis: 0 %(61 d) Method: FDA 3.09	

### 12.3 Bioaccumulative potential

### Components:

(S)-3-[3-(tert-butylamino)-2-	hyd	roxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
Partition coefficient: n- octanol/water	:	log Pow: 1,48



## **Timolol Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.17	28.09.2024	1609200-00019	Date of first issue: 01.05.2017

### 12.4 Mobility in soil

No data available

#### 12.5 Results of PBT and vPvB assessment

### **Product:**

Assessment

This substance/mixture contains no components considered 1 to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

Assessment

The substance/mixture does not contain components consid-: ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

### **SECTION 13: Disposal considerations**

13.1 Waste treatment methods	
Product	<ul> <li>Dispose of in accordance with local regulations.</li> <li>According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.</li> <li>Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.</li> <li>Do not dispose of waste into sewer.</li> </ul>
Contaminated packaging	<ul> <li>Empty containers should be taken to an approved waste han- dling site for recycling or disposal.</li> <li>If not otherwise specified: Dispose of as unused product.</li> </ul>

### **SECTION 14: Transport information**

14.1 UN number or ID number		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.2 UN proper shipping name		

### ιhh

ADN	
-----	--

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Timolol Formulation**

Versi 2.17	on	Revision Date: 28.09.2024		DS Number: 09200-00019	Date of last issue: 06.04.2024 Date of first issue: 01.05.2017
	ADR		:	Not regulated as	a dangerous good
I	RID		:	Not regulated as	a dangerous good
I	MDG		:	Not regulated as	a dangerous good
I	ATA		:	Not regulated as	a dangerous good
14.3	Transp	port hazard class(es)			
1	ADN		:	Not regulated as	a dangerous good
	ADR		:	Not regulated as	a dangerous good
I	RID		:	Not regulated as	a dangerous good
I	MDG		:	Not regulated as	a dangerous good
I	ATA		:	Not regulated as	a dangerous good
14.4	Packir	ng group			
	ADN		:	Not regulated as	a dangerous good
1	ADR		:	Not regulated as	a dangerous good
I	RID		:	Not regulated as	a dangerous good
I	MDG		:	Not regulated as	a dangerous good
I		Cargo)	:	Not regulated as	a dangerous good
I	ATA (	Passenger)	:	Not regulated as	a dangerous good
14.5	Enviro	onmental hazards			
I	Not reg	gulated as a dangerous	s go	od	
	-	al precautions for use plicable	er		
14.7	Maritir	ne transport in bulk a	acco	ording to IMO inst	ruments
	Remar	ks	:	Not applicable for	product as supplied.

### **SECTION 15: Regulatory information**

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)

: Conditions of restriction for the following entries should be considered: Number on list 3

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Timolol Formulation**

Version 2.17	Revision Date: 28.09.2024	SDS Number: 1609200-00019		of last issue: 06.04.2024 of first issue: 01.05.2017	
		ubstances of Very High	h	not. Not applicable	
Concern for Authorisation (Article 59). REACH - List of substances subject to authorisation			1	Not applicable	
(Annex XIV) Regulation (EC) on substances that deplete the ozone layer			ne	Not applicable	
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)			ollu-	Not applicable	
Regul ment	ation (ÉU) No 649/201	2 of the European Parlian ning the export and imp		Not applicable	

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

### Other regulations:

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

#### The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

### **SECTION 16: Other information**

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
Full text of H-Statements		
H302	:	Harmful if swallowed.
H361d	:	Suspected of damaging the unborn child.
H372	:	Causes damage to organs through prolonged or repeated
		exposure.
Full text of other abbreviation	ns	
Aguto Tox		A quite toxicity

Acute Tox.	:	Acute toxicity
Repr.	:	Reproductive toxicity
STOT RE	:	Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard



## **Timolol Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.17	28.09.2024	1609200-00019	Date of first issue: 01.05.2017

of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data Sheet		eChem Portal search results and European Chemicals Agen-
Sheet		cy, http://echa.europa.eu/

#### **Classification of the mixture:**

STOT RE 1 H372

# Classification procedure:

Based on product data or assessment

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN